In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS)

B. Sarina, A. Cortelezzi, C. Cattaneo, M. Pomati, I. Silvestris, M. Di Stefano, D. Lambertenghi-Deliliers, C. Hu, M. Monza, A. T. Maiolo

Research output: Contribution to journalArticle

Abstract

We evaluated the in vitro effects of IL-12, alone and in association with IL-2 on MDS bone marrow and peripheral blood cells. Thirty-six patients and 14 healthy subjects were studied. Natural killer-activity (NK-a) levels and lymphocyte immunophenotypes were determined in fresh bone marrow (BMMNC) and peripheral blood mononuclear cells (PBMNC), which then were resuspended in medium containing IL-2, IL-12 or IL-2 + IL-12 for 7 days. Re-evaluation of NK-a levels, lymphocyte immunophenotypes, clonogenic activity and cytokine release showed that, unlike IL-2, IL-12 did not significantly increase NK-a or CD3-/56+ cell levels in either bone marrow or peripheral blood; IL-2 + 12 led to a significant increase that fell between the values reached by each cytokine alone. IL-2 + 12 and, although to a lesser extent, also IL-12 alone induced the release of large amounts of γ-IFN and α-TNF. In addition, the number of clusters particularly decreased in the samples treated with IL-2 + 12 and IL-12 alone. Clonogenic activity was not modified after stimulation with any of the treatment. These data suggest that IL-12 induces the release of inhibitory cytokines in normal as well as MDS cells and that it could be used in patients with elevated bone marrow blastosis.

Original languageEnglish
Pages (from-to)1726-1731
Number of pages6
JournalLeukemia
Volume11
Issue number10
Publication statusPublished - 1997

Fingerprint

Myelodysplastic Syndromes
Interleukin-12
Natural Killer Cells
Interleukin-2
Cytokines
Bone Marrow
Blood Cells
In Vitro Techniques
Lymphocytes
Interleukin-7
Population Growth
Healthy Volunteers

Keywords

  • Clonogenic activity
  • Interleukin-12
  • Interleukin-2
  • Myelodysplastic syndromes
  • NK activity

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS). / Sarina, B.; Cortelezzi, A.; Cattaneo, C.; Pomati, M.; Silvestris, I.; Di Stefano, M.; Lambertenghi-Deliliers, D.; Hu, C.; Monza, M.; Maiolo, A. T.

In: Leukemia, Vol. 11, No. 10, 1997, p. 1726-1731.

Research output: Contribution to journalArticle

Sarina, B, Cortelezzi, A, Cattaneo, C, Pomati, M, Silvestris, I, Di Stefano, M, Lambertenghi-Deliliers, D, Hu, C, Monza, M & Maiolo, AT 1997, 'In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS)', Leukemia, vol. 11, no. 10, pp. 1726-1731.
Sarina, B. ; Cortelezzi, A. ; Cattaneo, C. ; Pomati, M. ; Silvestris, I. ; Di Stefano, M. ; Lambertenghi-Deliliers, D. ; Hu, C. ; Monza, M. ; Maiolo, A. T. / In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS). In: Leukemia. 1997 ; Vol. 11, No. 10. pp. 1726-1731.
@article{74e91da7bb254c089c42d51a82b3e1d0,
title = "In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS)",
abstract = "We evaluated the in vitro effects of IL-12, alone and in association with IL-2 on MDS bone marrow and peripheral blood cells. Thirty-six patients and 14 healthy subjects were studied. Natural killer-activity (NK-a) levels and lymphocyte immunophenotypes were determined in fresh bone marrow (BMMNC) and peripheral blood mononuclear cells (PBMNC), which then were resuspended in medium containing IL-2, IL-12 or IL-2 + IL-12 for 7 days. Re-evaluation of NK-a levels, lymphocyte immunophenotypes, clonogenic activity and cytokine release showed that, unlike IL-2, IL-12 did not significantly increase NK-a or CD3-/56+ cell levels in either bone marrow or peripheral blood; IL-2 + 12 led to a significant increase that fell between the values reached by each cytokine alone. IL-2 + 12 and, although to a lesser extent, also IL-12 alone induced the release of large amounts of γ-IFN and α-TNF. In addition, the number of clusters particularly decreased in the samples treated with IL-2 + 12 and IL-12 alone. Clonogenic activity was not modified after stimulation with any of the treatment. These data suggest that IL-12 induces the release of inhibitory cytokines in normal as well as MDS cells and that it could be used in patients with elevated bone marrow blastosis.",
keywords = "Clonogenic activity, Interleukin-12, Interleukin-2, Myelodysplastic syndromes, NK activity",
author = "B. Sarina and A. Cortelezzi and C. Cattaneo and M. Pomati and I. Silvestris and {Di Stefano}, M. and D. Lambertenghi-Deliliers and C. Hu and M. Monza and Maiolo, {A. T.}",
year = "1997",
language = "English",
volume = "11",
pages = "1726--1731",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS)

AU - Sarina, B.

AU - Cortelezzi, A.

AU - Cattaneo, C.

AU - Pomati, M.

AU - Silvestris, I.

AU - Di Stefano, M.

AU - Lambertenghi-Deliliers, D.

AU - Hu, C.

AU - Monza, M.

AU - Maiolo, A. T.

PY - 1997

Y1 - 1997

N2 - We evaluated the in vitro effects of IL-12, alone and in association with IL-2 on MDS bone marrow and peripheral blood cells. Thirty-six patients and 14 healthy subjects were studied. Natural killer-activity (NK-a) levels and lymphocyte immunophenotypes were determined in fresh bone marrow (BMMNC) and peripheral blood mononuclear cells (PBMNC), which then were resuspended in medium containing IL-2, IL-12 or IL-2 + IL-12 for 7 days. Re-evaluation of NK-a levels, lymphocyte immunophenotypes, clonogenic activity and cytokine release showed that, unlike IL-2, IL-12 did not significantly increase NK-a or CD3-/56+ cell levels in either bone marrow or peripheral blood; IL-2 + 12 led to a significant increase that fell between the values reached by each cytokine alone. IL-2 + 12 and, although to a lesser extent, also IL-12 alone induced the release of large amounts of γ-IFN and α-TNF. In addition, the number of clusters particularly decreased in the samples treated with IL-2 + 12 and IL-12 alone. Clonogenic activity was not modified after stimulation with any of the treatment. These data suggest that IL-12 induces the release of inhibitory cytokines in normal as well as MDS cells and that it could be used in patients with elevated bone marrow blastosis.

AB - We evaluated the in vitro effects of IL-12, alone and in association with IL-2 on MDS bone marrow and peripheral blood cells. Thirty-six patients and 14 healthy subjects were studied. Natural killer-activity (NK-a) levels and lymphocyte immunophenotypes were determined in fresh bone marrow (BMMNC) and peripheral blood mononuclear cells (PBMNC), which then were resuspended in medium containing IL-2, IL-12 or IL-2 + IL-12 for 7 days. Re-evaluation of NK-a levels, lymphocyte immunophenotypes, clonogenic activity and cytokine release showed that, unlike IL-2, IL-12 did not significantly increase NK-a or CD3-/56+ cell levels in either bone marrow or peripheral blood; IL-2 + 12 led to a significant increase that fell between the values reached by each cytokine alone. IL-2 + 12 and, although to a lesser extent, also IL-12 alone induced the release of large amounts of γ-IFN and α-TNF. In addition, the number of clusters particularly decreased in the samples treated with IL-2 + 12 and IL-12 alone. Clonogenic activity was not modified after stimulation with any of the treatment. These data suggest that IL-12 induces the release of inhibitory cytokines in normal as well as MDS cells and that it could be used in patients with elevated bone marrow blastosis.

KW - Clonogenic activity

KW - Interleukin-12

KW - Interleukin-2

KW - Myelodysplastic syndromes

KW - NK activity

UR - http://www.scopus.com/inward/record.url?scp=16944364153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944364153&partnerID=8YFLogxK

M3 - Article

C2 - 9324294

AN - SCOPUS:16944364153

VL - 11

SP - 1726

EP - 1731

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -